A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Trial Profile

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease; Rectal fistula
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 08 May 2017 New source identified and integrated: European Clinical Trials Database (EudraCT2016-003153-15).
    • 13 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 15 Mar 2017 Status changed to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top